NCT03253562

Metformin Versus Vildagliptin for Diabetic Hypertensive Patients

Comparative Efficacy and Safety of Vildagliptin Versus Metformin in Reduction of Cardiovascular Complications in Type 2 Diabetic Patients With Hypertension

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: MTI University · Academic / Other
• Sex: Female
• Age: 40 Years – 60 Years
• Healthy volunteers: Accepted

Summary

This is a controlled study to measure the efficacy of using metformin or vildagliptin for type 2 diabetic patients who suffers from hypertension to reduce cardiovascular risk resulting from both diabetes and hypertension using different parameters measuring

Detailed description

Several studies indicated that type 2 diabetes mellitus and hypertension are associated with increased cardiovascular complications. Recently, studies suggest that metformin and vildagliptin can reduce cardiovascular complications in diabetic patients with unclear mechanisms. This work aimed to determine the effect of metformin and vildagliptin on diabetic-hypertensive patients. Patients were allocated into four groups: groupI: healthy volunteers, groupII: patients recently diagnosed with their hypertension and diabetes, groupIII: patients treated with captopril (25mg once daily) for their hypertension in addition to metformin (1000mg bid) groupIV: patients treated with captopril (25mg bid) for hypertension in addition to vildagliptin (50mg bid). At the end of the therapeutic period, then total cholesterol, LDL,serum Creatinine level, blood pressure and vascular endothelial growth factor (VEGF) levels in serum will be measured for different groups to estimate the benefits of one drug over the other one in protecting against cardiovascular risks for diabetic hypertensive patients..

Conditions

• Reducing the Elevated Blood Pressure for Diabetic Hypertensive Patients

Interventions

Type	Name	Description
DRUG	Metformin Pill	a biguanide used as an insulin sensitizer for patients suffering from type 2 diabetes mellitus
DRUG	Vildagliptin 50 mg	Dpp4i antihyperglycemic drug used for treatment of type 2 diabetes mellitus

Timeline

• Start date: 2017-02-01
• Primary completion: 2017-08-01
• Completion: 2017-08-01
• First posted: 2017-08-18
• Last updated: 2017-08-18

Locations

1 site across 1 country: Egypt